Search

Search bills, members, committees and pages...

Sign In

H.R. 3375

U.S. House•In House Committee

Summary

H.R. 3375, the Fair Prescription Drug Prices for Americans Act, was introduced in the House on May 13, 2025 by Rep. Jeff Van Drew (R). It was referred to Energy And Commerce, and last saw action on May 13, 2025: Referred to the House Committee on Energy and Commerce.

Record

Text

H.R. 3375 has no co-sponsors and has not gone to a roll call.

hb3375/introduced-in-house.txt
119 HR 3375 IH: Fair Prescription Drug Prices for Americans Act
 U.S. House of Representatives
 2025-05-13
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 3375  IN THE HOUSE OF REPRESENTATIVES   May 13, 2025   Mr. Van Drew  introduced the following bill; which was referred to the  Committee on Energy and Commerce    A BILL
To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.
1.
Short title
This Act may be cited as the   Fair Prescription Drug Prices for Americans Act  .
2.
International reference pricing for prescription drugs and biological products
(a)
Definitions
In this section:
(1)
Biological product
The term  biological product  means a biological product licensed under subsection (a) or (k) of section 351 of the Public Health Service Act ( 42 U.S.C. 262 ).
(2)
Drug
The term  drug  means a drug approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ).
(3)
Secretary
The term  Secretary  means the Secretary of Health and Human Services.
(b)
Cap on retail list price of prescription drugs and biological products
The retail list price in the United States for a drug or a biological product may not exceed the average retail list price for the drug or biological product among Canada, France, Germany, Italy, Japan, and the United Kingdom, as calculated under subsection (c).
(c)
Calculation of average retail list price
The Secretary shall calculate on an annual basis the average retail list price for each drug and biological product sold in Canada, France, Germany, Italy, Japan, and the United Kingdom, through a combination of data reported by manufacturers of drugs and biological products under subsection (e) and data obtained through review of publicly filed materials by manufacturers of drugs and biological products in such countries.
(d)
Civil monetary penalty
(1)
In general
Any manufacturer that violates subsection (b) with respect to a drug or biological product shall be subject to a civil monetary penalty imposed by the Secretary in amount equal to the product obtained by multiplying—
(A)
the difference between—
(i)
the list price for the drug or biological product sold in the United States; and
(ii)
the average retail list price for the drug or biological product sold in Canada, France, Germany, Italy, Japan, and the United Kingdom, as calculated under subsection (c); and
(B)
10.
(2)
Requirement
The amount of a civil monetary penalty under paragraph (1) shall be calculated and charged for each unit of drug or biological product sold.
(e)
Data collection
Each manufacturer of a drug or biological product shall submit to the Secretary on an annual basis—
(1)
the list price for the drug or biological product sold in the United States; and
(2)
the list price for the drug or biological product sold in each of Canada, France, Germany, Italy, Japan, and the United Kingdom.
(f)
Guidance and regulations
The Secretary shall issue guidance and promulgate regulations to implement this section.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-05-13
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.

Sponsors

Rep. Jeff Van Drew (R) sponsors H.R. 3375 alone.

Jeff Van Drew

Rep. · R–NJ-2 · Sponsor

Committees

H.R. 3375 went before 1 committee: Energy and Commerce.

Energy and Commerce
Energy and Commerce
Referred To · May 13, 2025 · 1,636 Bills

Actions

H.R. 3375 has taken 2 actions since May 13, 2025.

ChamberAction
May 13, 2025
House
Introduced in House
May 13, 2025
House
Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee

Votes

H.R. 3375 has not gone to a roll call.

1 bill is related to H.R. 3375.

Titles

H.R. 3375 goes by 3 titles, 1 of them short titles.

  • Fair Prescription Drug Prices for Americans Act — Display Title
  • Fair Prescription Drug Prices for Americans Act — Short Title(s) as Introduced
  • To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations. — Official Title as Introduced

Lobbying

3 clients hired 3 firms and 17 registered lobbyists who named H.R. 3375 in 8 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Budget/Appropriations, Tariff (miscellaneous tariff bills), Immigration, Agriculture, Animals, Chemicals/Chemical Industry, Copyright/Patent/Trademark.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
GRIFOLS SHARED SERVICES NORTH AMERICA INC—District of Columbia15—
HEALTHCARE INSTITUTE OF NEW JERSEY—New Jersey12—
BIOTECHNOLOGY INNOVATION ORGANIZATION—District of Columbia11—

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
GRIFOLS SHARED SERVICES NORTH AMERICA, INC.15—
HEALTHCARE INSTITUTE OF NEW JERSEY12—
BIOTECHNOLOGY INNOVATION ORGANIZATION11—

Lobbyists

Named on the filings that cite the bill.

LobbyistFirmsClientsFilings
CHRISTOPHER HEALEY115
KATHERINE PAJEWSKI115
MICHAEL PIERSALL115
ROSEMARY GARZA115
STEVE ISSENMAN112
AIKEN HACKETT111
AMBER MANKO111
BAILEY MCCUE111
CHRIS JONES111
DAVID LACHMANN111
ELISABETH FOX111
EMILY WHEELER111
HANSJORG SAUER111
JOHN TORRES111
KRISTIN MURPHY111
PHYLLIS ARTHUR111
PRANEEL JADAV111

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
BIOTECHNOLOGY INNOVATION ORGANIZATIONBIOTECHNOLOGY INNOVATION ORGANIZATION2025 second_quarter$1.8M2nd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2026 first_quarter$480K1st Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2025 fourth_quarter$470K4th Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2025 third_quarter$450K3rd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2025 second_quarter$390K2nd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2026 second_quarter$370K2nd Quarter - Report
HEALTHCARE INSTITUTE OF NEW JERSEYHEALTHCARE INSTITUTE OF NEW JERSEY2026 first_quarter$51K1st Quarter - Report
HEALTHCARE INSTITUTE OF NEW JERSEYHEALTHCARE INSTITUTE OF NEW JERSEY2026 second_quarter$47.7K2nd Quarter - Report

Classification

The Congressional Research Service files H.R. 3375 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 3375’s is Health.

hr3375/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Source: congress.gov · legiscan.com